<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary R Lichtenstein, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tumor necrosis factor (TNF)-alpha inhibitors, including <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>, are biologic agents used for treating patients with moderately to severely active Crohn disease. </p><p>Dosing, monitoring, and adverse effects of anti-TNF agents for the treatment of Crohn disease in adults will be reviewed here. The decision whether to use <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, or <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a> in patients requiring anti-TNF-alpha therapy is influenced by the indication, patient preference, patient medical history, and availability in individual countries. Overviews of the medical management of Crohn disease and use of thiopurines are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4084.html" rel="external">"Management of Crohn disease after surgical resection"</a>.)</p><p></p><p class="headingAnchor" id="H170611863"><span class="h1">TUMOR NECROSIS FACTOR INHIBITORS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a> are monoclonal antibodies directed against tumor necrosis factor (TNF)-alpha. The basis for their use in Crohn disease is that tumor necrosis factor (TNF)-alpha has several biologic activities that may be directly related to the pathogenesis of inflammatory bowel disease and to the dysregulation of the immune system that occurs in patients with IBD. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Anticytokine approaches'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a><strong> </strong>–<strong> </strong>Infliximab is a chimeric monoclonal antibody comprised of 75 percent human and 25 percent murine sequences, which has a high specificity for and affinity to tumor necrosis factor (TNF)-alpha. Infliximab neutralizes the biologic activity of TNF-alpha by inhibiting binding to its receptors. In contrast to some other TNF inhibitors (eg, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>), infliximab can also induce apoptosis of activated lymphocytes in the gut mucosa [<a href="#rid1">1-3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a><strong> </strong>–<strong> </strong>Adalimumab is a recombinant fully human monoclonal antibody that binds to TNF-alpha, thereby interfering with binding to TNF-alpha receptor sites and subsequent cytokine-driven inflammatory processes. The humanized construction of adalimumab is presumed to lower the risk of forming anti-drug antibodies compared with <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>. (See  <a class="medical medical_review" href="/z/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases", section on 'Adalimumab-induced human anti-human antibodies'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">Certolizumab pegol</a><strong> </strong>–<strong> </strong>Certolizumab pegol is a humanized monoclonal antibody Fab fragment linked to polyethylene glycol that increases its plasma half-life and reduces the requirement for frequent dosing, possibly reducing immunogenicity as well. In vitro studies suggest that certolizumab pegol also has a higher binding affinity for TNF as compared with <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> or <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">Certolizumab pegol</a> does not have an Fc region; as a result, it does not activate the complement pathway, result in cell- or antibody-mediated cytotoxicity, or induce apoptosis [<a href="#rid4">4</a>]. However, the clinical significance of these differences is unclear.</p><p></p><p class="headingAnchor" id="H3834231496"><span class="h1">PRETREATMENT SCREENING</span><span class="headingEndMark"> — </span>Prior to starting an anti-TNF agent, we obtain the following screening tests in all patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), and hepatitis B core antibody (HBcAb).</p><p></p><p class="bulletIndent1">Patients with serologic evidence of hepatitis B virus (HBV) infection (HBsAg-positive or anti-HBc-positive) are at risk for HBV reactivation if they receive immunosuppressive therapy. Prevention, diagnosis, and treatment of HBV reactivation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interferon-gamma release assay such as QuantiFERON-TB Gold In-Tube assay (preferred) or <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a>.</p><p></p><p class="bulletIndent1">If the screening test for latent tuberculosis is positive, a chest radiograph is obtained and the patient is referred to an infectious disease specialist for further evaluation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors", section on 'Screening'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p></p><p class="headingAnchor" id="H515977918"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>The contraindications to the use of anti-TNF therapies include the following (see  <a class="medical medical_review" href="/z/d/html/7790.html" rel="external">"Treatment of axial spondyloarthritis (ankylosing spondylitis and nonradiographic axial spondyloarthritis) in adults", section on 'Use of TNF inhibitors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Active, uncontrolled infection </p><p class="bulletIndent1"><span class="glyph">●</span>Latent (untreated) tuberculosis</p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating disease (eg, multiple sclerosis, optic neuritis)</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure (New York Heart Association class III/IV)  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 1</a>) </p><p class="bulletIndent1"><span class="glyph">●</span>Active lymphoma</p><p></p><p>The safety of anti-TNF therapies and risk of recurrent malignancy in patients with a history of malignancy is less well established than in patients without such a history; the available data are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p class="headingAnchor" id="H3885270760"><span class="h1">DOSING AND ADMINISTRATION</span></p><p class="headingAnchor" id="H3579305105"><span class="h2">Overview</span><span class="headingEndMark"> — </span>This section describes the induction and maintenance dosing for <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>. In addition, options for dose escalation are included for patients with loss of response while on maintenance therapy. The approach to the patient who is not responding to induction anti-TNF therapy, including the use of adjuvant glucocorticoids or immunomodulators, is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Induction therapy'</a>.) </p><p>Decisions regarding dose adjustments for patients on maintenance therapy who lose response can be guided by therapeutic drug monitoring  (<a class="graphic graphic_table graphicRef117391" href="/z/d/graphic/117391.html" rel="external">table 2</a>). (See <a class="local">'Monitoring'</a> below and  <a class="medical medical_review" href="/z/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Monitoring'</a>.) </p><p class="headingAnchor" id="H1553722763"><span class="h2">Infliximab</span><span class="headingEndMark"> — </span>The induction dose of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> for treatment of patients with moderately to severely active Crohn disease, including fistulizing disease, is 5 mg/kg intravenously at zero-, two-, and six- weeks [<a href="#rid5">5,6</a>]. </p><p>Patients who achieve an adequate response (based on clinical, endoscopic, and laboratory findings) to initial therapy will require maintenance therapy with repeat infusions of 5 mg/kg, usually every eight weeks. Beginning at week 10 of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> therapy, an alternative to intravenous administration is subcutaneous injection [<a href="#rid7">7</a>]. Infliximab 120 mg is given subcutaneously once every two weeks. </p><p>Patients who have a disease flare while on maintenance dosing can be managed by escalating the dose [<a href="#rid8">8</a>]. Additionally, individuals who achieve an incomplete response can be managed in a similar fashion. Dose escalation can be accomplished by either decreasing the dosing interval or by increasing the dose (eg, from 5 mg/kg to 10 mg/kg). The maximal dose of <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> is 10 mg/kg every four weeks. </p><p class="headingAnchor" id="H1745305422"><span class="h2">Adalimumab</span><span class="headingEndMark"> — </span>Induction therapy with <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> is given subcutaneously with the following regimen:</p><p class="bulletIndent1"><span class="glyph">●</span>Week zero, initial dose: 160 mg once</p><p class="bulletIndent1"><span class="glyph">●</span>Week two: 80 mg once</p><p class="bulletIndent1"><span class="glyph">●</span>Week four and thereafter: 40 mg every other week (maintenance dose)</p><p></p><p>We suggest the same induction regimen for patients who are being switched to <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> from another anti-tumor necrosis factor (TNF) agent. Adalimumab is available in a single-use prefilled pen (Humira Pen) or in a single-use prefilled glass syringe. </p><p>For patients who have a disease flare while on maintenance dosing, the dosing interval can be shortened to every week [<a href="#rid9">9</a>]. A meta-analysis of 39 studies showed that the mean percentage of loss of response to <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> among primary responders was 18 percent and the annual risk was 20 percent per patient-year; the mean percentage of patients who required dose escalation (ie, shortening the dosing interval) among primary responders to adalimumab was 37 percent and the annual risk was 25 percent per patient-year [<a href="#rid10">10</a>].</p><p>In this pooled analysis of outcomes following dose escalation, response was achieved in 71 percent of patients, and remission was achieved in 40 percent of patients [<a href="#rid10">10</a>]. A large number of factors predicted loss of response or need for dose escalation in patients treated with <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> (male sex, high body mass index, current/former smoking, family history of inflammatory bowel disease, isolated colonic disease, extraintestinal manifestations, 80/40 mg induction therapy, longer disease duration, greater baseline Crohn Disease Activity Index, concomitant glucocorticoid use, absence of deep remission at week 12, low serum trough concentrations of adalimumab, previous <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> non-response, and prior treatment with an anti-TNF-alpha agent) [<a href="#rid10">10,11</a>].</p><p>In addition to loss of response, some patients do not respond initially to anti-TNF induction therapy (primary nonresponse), and rates of primary nonresponse have ranged from 10 to 40 percent in clinical trials and observational studies [<a href="#rid12">12</a>]. In addition, studies have suggested that primary nonresponse has often been related to inadequate drug concentrations [<a href="#rid13">13</a>]. Thus, it seems most appropriate to escalate the dose of anti-TNF therapy during induction for patients who are not responding and utilize therapeutic drug monitoring. (See <a class="local">'Therapeutic drug monitoring'</a> below.)</p><p class="headingAnchor" id="H2401709420"><span class="h2">Certolizumab pegol</span><span class="headingEndMark"> — </span>The recommended dose of <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a> for induction of remission in Crohn disease is 400 mg subcutaneously at weeks zero, two, and four, and then every four weeks for maintenance therapy [<a href="#rid14">14</a>]. For patients who have loss of response while on maintenance dosing and who are candidates for dose escalation, options include shortening the interval between doses (eg, every two to three weeks) or giving a single re-induction dose (ie, 400 mg) between scheduled four-week doses [<a href="#rid15">15,16</a>]. </p><p class="headingAnchor" id="H2650467141"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>In addition to clinical observation, monitoring the response to anti-TNF agents may include therapeutic drug monitoring (checking drug trough levels, anti-drug antibodies) and levels of biomarkers (C-reactive protein [CRP], fecal calprotectin). Time intervals for follow-up colonoscopy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H3350433340"><span class="h2">Therapeutic drug monitoring</span><span class="headingEndMark"> — </span>Therapeutic drug monitoring involves measuring serum drug trough concentrations and antidrug antibodies to optimize the use of anti-TNF agents for patients with inflammatory bowel disease (IBD). For patients with clinical features of inflammation (eg, symptoms, laboratory studies, endoscopic appearance), therapeutic drug monitoring can help the clinician decide whether a dose increase is needed or if switching to a different drug is preferred. Approximately 40 percent of patients who initially achieve remission will develop secondary loss of response during the first year of therapy [<a href="#rid5">5,17</a>]. Potential causes of secondary loss of response include  (<a class="graphic graphic_table graphicRef117391" href="/z/d/graphic/117391.html" rel="external">table 2</a>) [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Low drug levels (due to either immune or non-immune mediated clearance mechanisms)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mechanistic failure (eg, non-TNF-mediated cytokine pathways may be playing a greater role in pathogenesis of IBD)</p><p></p><p>Available drug assays report both drug concentration and anti-drug antibodies. The suggested target drug trough concentrations are generally based on cross-sectional studies of patients on maintenance therapy [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a>: ≥5 mcg/mL for luminal disease. Some but not all studies have reported that higher infliximab trough levels were associated with healing of perianal fistula related to Crohn disease [<a href="#rid19">19-23</a>], and a trough level of ≥10 mcg/mL has been suggested for patients with fistulizing disease [<a href="#rid20">20</a>].<strong> </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">Adalimumab</a>: ≥7.5 mcg/mL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">Certolizumab pegol</a>: ≥20 mcg/mL.</p><p></p><p class="headingAnchor" id="H2236192710"><span class="h3">Patients with active disease despite maintenance therapy</span><span class="headingEndMark"> — </span>A guideline from the American Gastroenterological Association (AGA) suggests that adult patients with active inflammatory bowel disease who are being treated with an anti-TNF agent receive reactive therapeutic drug monitoring using drug trough levels and anti-drug antibodies [<a href="#rid18">18</a>]. The drug trough level should be drawn no more than 24 hours prior to the next scheduled dose of the drug. Measurement of drug levels and anti-drug antibodies with dose adjustments to reach a target drug trough concentration can result in fewer flares during the course of treatment and is more cost-effective compared with empiric dose escalation in patients with a loss of response  (<a class="graphic graphic_algorithm graphicRef143130" href="/z/d/graphic/143130.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef117391" href="/z/d/graphic/117391.html" rel="external">table 2</a>) [<a href="#rid24">24-26</a>]. Because antibodies to anti-TNF agents can reduce drug blood levels, a subset of patients will lose their response and have recurrence of symptoms between treatment intervals. </p><p class="headingAnchor" id="H3886355621"><span class="h4">Patients with detectable anti-drug antibodies</span><span class="headingEndMark"> — </span>For patients with high levels of anti-drug antibodies, we typically discontinue the index agent and switch to another drug  (<a class="graphic graphic_algorithm graphicRef143130" href="/z/d/graphic/143130.html" rel="external">algorithm 1</a>). If the patient has adequate (ie, therapeutic) drug trough concentrations, switching to a drug from another class (eg, anti-integrin antibody [<a class="drug drug_general" data-topicid="95501" href="/z/d/drug information/95501.html" rel="external">vedolizumab</a>], anti-IL-12/23 antibody [<a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a>], anti-IL-23 antibody [<a class="drug drug_general" data-topicid="121112" href="/z/d/drug information/121112.html" rel="external">risankizumab</a>]) is preferred [<a href="#rid18">18,27</a>]. If the patient has high anti-drug antibody levels and inadequate (ie, subtherapeutic) drug trough concentrations, options include switching to an alternative anti-TNF agent (with or without an immunomodulator) or switching to a drug from another class. </p><p>Transient or low-level anti-drug antibodies can disappear spontaneously or can be overcome by dose optimization when drug concentrations are low, whereas sustained, high anti-drug antibody levels may lead to permanent loss of response and necessitate discontinuation of the index drug. In contrast to target drug trough concentrations, the reporting of anti-drug antibodies has varied among commercial assays and has not been standardized [<a href="#rid18">18</a>]. (See <a class="local">'Therapeutic drug monitoring'</a> above.)</p><p>For patients with anti-drug antibodies who switch to a different biologic agent within the same class, the addition of an immunomodulator may be helpful. The use of immunomodulators (ie, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a> or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>) decreases the rate of formation of antibodies to anti-TNF agents and results in higher response and remission rates [<a href="#rid28">28-30</a>]. In a meta-analysis of 24 studies including over 4600 patients with inflammatory bowel disease, patients who were treated with combination therapy (ie, anti-TNF agent and immunomodulator) were less likely to develop antibodies against tumor necrosis factor antagonists (anti-TNFs) compared with patients treated with anti-TNF monotherapy (RR 0.49, 95% CI 0.41-0.59) [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/z/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a>.) </p><p>Data also suggested that patients who develop antibodies against one anti-TNF agent were more likely to develop antibodies against another anti-TNF agent, thus highlighting this concept [<a href="#rid31">31</a>].</p><p>One retrospective study analyzed 788 serum samples from 57 infliximab-treated patients with IBD in whom anti-infliximab antibodies had been detected at least once during follow-up [<a href="#rid32">32</a>]. In this study, patients with transient anti-infliximab antibodies had lower median anti-infliximab antibodies levels than those with persistent antibodies (6 and 18 units/mL respectively). In patients with transient anti-infliximab antibodies, antibodies disappeared spontaneously or after <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> dose optimization in 42 and 58 percent, respectively. A higher proportion of patients with persistent anti-infliximab antibodies discontinued treatment as compared with those with transient antibodies (74 versus 26 percent). </p><p class="headingAnchor" id="H849061288"><span class="h3">Patients in remission</span><span class="headingEndMark"> — </span>While therapeutic drug monitoring is useful in the setting of active IBD (ie, reactive drug monitoring), we do not routinely use therapeutic drug monitoring for patients in clinical remission (ie, proactive drug monitoring) because data from randomized trials suggested that proactive monitoring did not improve outcomes. We reserve proactive monitoring for patients who are at higher risk of complications from a disease flare. In a meta-analysis of nine trials including 1405 patients with IBD who were in remission, there were no significant differences in rates of sustained remission, anti-drug antibodies, or serious adverse events between patients who had proactive drug monitoring compared with conventional management [<a href="#rid33">33</a>]. (See <a class="local">'Therapeutic drug monitoring'</a> above.)</p><p class="headingAnchor" id="H3280892475"><span class="h2">Biomarkers of inflammation</span><span class="headingEndMark"> — </span>In addition to therapeutic drug monitoring, obtaining biomarkers of inflammation including CRP and fecal calprotectin can help guide therapy to achieve endoscopic and clinical remission in patients with Crohn disease [<a href="#rid34">34,35</a>]. Although the AGA has published guidelines on therapeutic drug monitoring, biomarker monitoring is used at the discretion of the clinician.</p><p>Biomarkers of inflammation are typically obtained before initiating therapy, and as an example, CRP levels have been used to predict response to treatment [<a href="#rid36">36,37</a>]. In addition, elevated biomarkers can be followed after initiating biologic therapy to see if the biomarkers improve with treatment.</p><p>In a trial of 244 patients with Crohn disease, patients who were monitored by clinical symptoms and with biomarkers (ie, CRP and fecal calprotectin) and in whom biologic and/or immunomodulator therapy was started and escalated based on those results, were more likely to have mucosal healing at 48 weeks compared with patients who were monitored by clinical symptoms alone (46 versus 30 percent, adjusted risk difference 16 percent [95% CI 3.9-28.3]) [<a href="#rid34">34</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>CRP – A high baseline CRP level that normalizes with treatment has been associated with a higher chance of having a response to <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> [<a href="#rid28">28,38</a>]. In a study of 718 patients with Crohn disease who were receiving infliximab, patients with elevated CRP levels before treatment were more likely to respond to infliximab compared with patients with normal levels (91 versus 83 percent) [<a href="#rid38">38</a>]. Early normalization of the CRP level was associated with a sustained, long-term response and CRP levels remained significantly higher in patients who lost their response to infliximab than in patients who had a sustained response. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fecal calprotectin – Fecal calprotectin can be used to monitor response to anti-TNF therapy in patients with IBD, but because of limited sensitivity and specificity it should be used in conjunction with other laboratory tests and symptoms to arrive at clinical decisions [<a href="#rid39">39</a>]. Fecal calprotectin levels correlate with endoscopic disease activity and may differentiate between active and inactive IBD [<a href="#rid40">40-43</a>]. Calprotectin is a zinc and calcium binding protein that is derived mostly from neutrophils and monocytes, and fecal calprotectin levels are increased in patients with mucosal inflammation. (See  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings", section on 'General laboratory tests'</a>.)</p><p></p><p class="headingAnchor" id="H1300341850"><span class="h1">ADVERSE EVENTS</span><span class="headingEndMark"> — </span>The tumor necrosis factor (TNF)-alpha inhibitors have multiple potential adverse events that are listed below and discussed in more detail separately [<a href="#rid44">44-47</a>] (see  <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Infection (see  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malignancy (see  <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Induction of autoimmunity (see  <a class="medical medical_review" href="/z/d/html/7974.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Demyelinating disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Injection site reactions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infusion reactions  (<a class="graphic graphic_table graphicRef85654" href="/z/d/graphic/85654.html" rel="external">table 3</a> and <a class="graphic graphic_algorithm graphicRef85655" href="/z/d/graphic/85655.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous reactions, including psoriaform lesions (suggest referring the patients with skin lesions to dermatology for further evaluation).</p><p></p><p>Severe adverse reactions may result in discontinuation of anti-TNF therapy. In other cases, the reaction may be manageable, and stopping anti-TNF therapy may not be necessary.</p><p class="headingAnchor" id="H3806877877"><span class="h2">Risks with combination therapy</span><span class="headingEndMark"> — </span>The risk of lymphoma in patients on <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a> (or other anti-TNF agents) in combination with an immunomodulator (<a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9612" href="/z/d/drug information/9612.html" rel="external">6-mercaptopurine</a>), along with an increased incidence of infections in patients on more than one immunosuppressive agent, has led to the use of anti-TNF monotherapy in some patients with IBD. </p><p>The magnitude of the risk of developing lymphoma is low when viewed in absolute terms (ie, less than one case per 1000 person years) [<a href="#rid48">48</a>]. In a large cohort study including over 189,000 patients with inflammatory bowel disease, the risk of lymphoma was increased in patients exposed to combination therapy (adjusted hazard ratio [aHR] 6.11, 95% CI 3.46-10.8), anti-TNF monotherapy (aHR 2.41, 95% CI 1.6-3.64), or thiopurine monotherapy (aHR 2.6, 95% CI 1.96-3.44) compared with patients who were not exposed to any of these drug regimens during a median follow-up of 6.7 years [<a href="#rid48">48</a>].</p><p>Long-term thiopurine use (more than two years) appears to be a common denominator in cases of hepatosplenic T-cell lymphomas, and this issue is addressed separately [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Hepatosplenic T-cell lymphoma'</a>.) </p><p class="headingAnchor" id="H21"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>The use of anti-TNF agents during pregnancy and lactation is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4083.html" rel="external">"Fertility, pregnancy, and nursing in inflammatory bowel disease", section on 'Anti-tumor necrosis factor agents'</a>.)</p><p class="headingAnchor" id="H717012290"><span class="h1">BIOSIMILARS FOR BIOLOGIC AGENTS</span><span class="headingEndMark"> — </span>Copies of biologic agents, including several of the tumor necrosis factor inhibitors, have been marketed and are under development. A "biosimilar" is a copy which is similar but not identical to the original ("reference" or "legacy") product and is no longer under patent protection. Infliximab-dyyb is an example of a biosimilar. Biosimilars for biologic agents are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'Biosimilars for biologic agents'</a>.) </p><p class="headingAnchor" id="H2040015421"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p>The American Gastroenterological Association (AGA) guidelines on the use of anti-TNF agents for Crohn disease and on therapeutic drug monitoring can be accessed through <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgastro.org%2Fguidelines%2F&amp;token=sX8xxkPP8kKyhj3sZbNUo%2B8Hmrq5qECkcctuBeNGRNSEea0nbsHCdk0vj6CIumZ%2B&amp;TOPIC_ID=4078" target="_blank">the AGA website</a> [<a href="#rid18">18,50,51</a>]. In addition, the American College of Gastroenterology (ACG) has issued practice guidelines that can be accessed through <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgi.org%2Fguidelines%2F&amp;token=Og4ss9xZ8giAwuAeSJ0YNc6skx84OvXZrMgtpdmNxqc7PB%2F4DeCjmena7knDpUfp&amp;TOPIC_ID=4078" target="_blank">the ACG website</a> [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H1630695215"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15383.html" rel="external">"Patient education: Crohn disease in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2004.html" rel="external">"Patient education: Crohn disease (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H25"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-tumor necrosis factor (TNF) therapy</strong> – Tumor necrosis factor (TNF)-alpha inhibitors, including <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>, are biologic agents used for treating patients with moderately to severely active Crohn disease. The decision whether to use infliximab, adalimumab, or certolizumab pegol in patients requiring anti-TNF therapy is influenced by the indication, patient preference, and availability in individual countries. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">Infliximab</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, and <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a> are all monoclonal antibodies directed against TNF-alpha. (See <a class="local">'Tumor necrosis factor inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications to use of anti-TNF agents</strong> – Contraindications to the use of anti-TNF therapies include the following (see <a class="local">'Contraindications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Active infection</p><p class="bulletIndent2"><span class="glyph">•</span>Latent (untreated) tuberculosis</p><p class="bulletIndent2"><span class="glyph">•</span>Demyelinating disease (eg, multiple sclerosis, optic neuritis)</p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure (NYHA class III/IV)  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 1</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Active lymphoma</p><p></p><p class="bulletIndent1">The safety of anti-TNF therapies and risk of recurrent malignancy in patients with a history of malignancy is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic drug monitoring</strong> – Therapeutic drug monitoring involves measuring serum drug trough concentrations and anti-drug antibodies to optimize the use of anti-TNF agents for patients with inflammatory bowel disease. Some patients who initially achieve remission will develop secondary loss of response. Reactive drug monitoring in this setting can help the clinician decide whether dose escalation is needed or if switching to a different drug is preferred  (<a class="graphic graphic_algorithm graphicRef143130" href="/z/d/graphic/143130.html" rel="external">algorithm 1</a>). </p><p></p><p class="bulletIndent1">For patients in clinical remission, we reserve therapeutic drug monitoring for patients at higher risk of complications from a disease flare, rather than performing it routinely in all patients. (See <a class="local">'Therapeutic drug monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse events</strong> – Potential adverse events associated with TNF-alpha inhibitors include (see <a class="local">'Adverse events'</a> above): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infection</p><p class="bulletIndent2"><span class="glyph">•</span>Malignancy</p><p class="bulletIndent2"><span class="glyph">•</span>Induction of autoimmunity</p><p class="bulletIndent2"><span class="glyph">•</span>Demyelinating disease</p><p class="bulletIndent2"><span class="glyph">•</span>Heart failure</p><p class="bulletIndent2"><span class="glyph">•</span>Injection site reactions</p><p class="bulletIndent2"><span class="glyph">•</span>Infusion reactions</p><p class="bulletIndent2"><span class="glyph">•</span>Neutropenia</p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous reactions, including psoriaform lesions</p><p></p><p class="headingAnchor" id="H3683997835"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff thank Dr. Richard MacDermott for his contributions as author to prior versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Paul Rutgeerts, MD (deceased), who contributed as a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lügering A, Schmidt M, Lügering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001; 121:1145.</a></li><li><a class="nounderline abstract_t">ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206.</a></li><li><a class="nounderline abstract_t">Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124:1774.</a></li><li><a class="nounderline abstract_t">Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323.</a></li><li><a class="nounderline abstract_t">Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541.</a></li><li><a class="nounderline abstract_t">Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398.</a></li><li class="breakAll">Infliximab. United States Prescribing Information. Revised October 2023. US Food &amp; Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761358s000lbl.pdf (Accessed on October 29, 2023).</li><li><a class="nounderline abstract_t">Roda G, Jharap B, Neeraj N, Colombel JF. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin Transl Gastroenterol 2016; 7:e135.</a></li><li><a class="nounderline abstract_t">D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199.</a></li><li><a class="nounderline abstract_t">Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011; 106:674.</a></li><li><a class="nounderline abstract_t">Bultman E, de Haar C, van Liere-Baron A, et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012; 35:335.</a></li><li><a class="nounderline abstract_t">Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 2014; 13:24.</a></li><li><a class="nounderline abstract_t">Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019; 4:341.</a></li><li><a class="nounderline abstract_t">Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807.</a></li><li><a class="nounderline abstract_t">Stein AC, Rubin DT, Hanauer SB, Cohen RD. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis 2014; 20:1722.</a></li><li><a class="nounderline abstract_t">Ehrenberg R, Griffith J, Theigs C, McDonald B. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease. J Manag Care Spec Pharm 2020; 26:758.</a></li><li><a class="nounderline abstract_t">Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52.</a></li><li><a class="nounderline abstract_t">Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology 2017; 153:827.</a></li><li><a class="nounderline abstract_t">Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. J Crohns Colitis 2017; 11:549.</a></li><li><a class="nounderline abstract_t">Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther 2017; 45:933.</a></li><li><a class="nounderline abstract_t">Strik AS, Löwenberg M, Buskens CJ, et al. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients. Scand J Gastroenterol 2019; 54:453.</a></li><li><a class="nounderline abstract_t">El-Matary W, Walters TD, Huynh HQ, et al. Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children. Inflamm Bowel Dis 2019; 25:150.</a></li><li><a class="nounderline abstract_t">Plevris N, Jenkinson PW, Arnott ID, et al. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease. Eur J Gastroenterol Hepatol 2020; 32:32.</a></li><li><a class="nounderline abstract_t">Ordás I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10:1079.</a></li><li><a class="nounderline abstract_t">Steenholdt C, Brynskov J, Thomsen OØ, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut 2014; 63:919.</a></li><li><a class="nounderline abstract_t">Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148:1320.</a></li><li><a class="nounderline abstract_t">Lee SD, Shivashankar R, Quirk D, et al. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021; 55:195.</a></li><li><a class="nounderline abstract_t">Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.</a></li><li><a class="nounderline abstract_t">Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601.</a></li><li><a class="nounderline abstract_t">Qiu Y, Mao R, Chen BL, et al. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clin Gastroenterol Hepatol 2017; 15:1359.</a></li><li><a class="nounderline abstract_t">Vande Casteele N, Abreu MT, Flier S, et al. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor. Clin Gastroenterol Hepatol 2022; 20:465.</a></li><li><a class="nounderline abstract_t">Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108:962.</a></li><li><a class="nounderline abstract_t">Nguyen NH, Solitano V, Vuyyuru SK, et al. Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Gastroenterology 2022; 163:937.</a></li><li><a class="nounderline abstract_t">Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017; 390:2779.</a></li><li><a class="nounderline abstract_t">Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol 2015; 110:1324.</a></li><li><a class="nounderline abstract_t">Cioffi M, Rosa AD, Serao R, et al. Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol 2015; 6:13.</a></li><li><a class="nounderline abstract_t">Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55:426.</a></li><li><a class="nounderline abstract_t">Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9:421.</a></li><li><a class="nounderline abstract_t">Sipponen T, Savilahti E, Kärkkäinen P, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008; 14:1392.</a></li><li><a class="nounderline abstract_t">Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105:162.</a></li><li><a class="nounderline abstract_t">Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103:162.</a></li><li><a class="nounderline abstract_t">Lobatón T, López-García A, Rodríguez-Moranta F, et al. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 2013; 7:e641.</a></li><li><a class="nounderline abstract_t">D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18:2218.</a></li><li><a class="nounderline abstract_t">Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126:19.</a></li><li><a class="nounderline abstract_t">Ljung T, Karlén P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53:849.</a></li><li><a class="nounderline abstract_t">Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95:3469.</a></li><li><a class="nounderline abstract_t">Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000; 95:3490.</a></li><li><a class="nounderline abstract_t">Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA 2017; 318:1679.</a></li><li><a class="nounderline abstract_t">Kotlyar DS, Blonski W, Diamond RH, et al. Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol 2010; 105:2299.</a></li><li><a class="nounderline abstract_t">Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021; 160:2496.</a></li><li><a class="nounderline abstract_t">Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology 2013; 145:1459.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2018; 113:481.</a></li></ol></div><div id="topicVersionRevision">Topic 4078 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11677207" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788561" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12806611" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636564" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12047962" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228190" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Infliximab for the treatment of fistulas in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228190" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infliximab for the treatment of fistulas in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26741065" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21045814" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21407178" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22191671" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23792214" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Optimizing anti-TNF treatments in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30824404" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143120" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25171509" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191593" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241859" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780013" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28453755" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28211593" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31032686" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29912413" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn's Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31567638" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22813440" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23878167" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25724455" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32740098" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393175" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Infliximab, azathioprine, or combination therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584368" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232073" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33421628" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419382" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Antibody response to infliximab and its impact on pharmacokinetics can be transient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35753383" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096949" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303131" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25685607" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Laboratory markers in ulcerative colitis: Current insights and future advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16474109" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Laboratory markers in IBD: useful, magic, or unnecessary toys?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21334460" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18484671" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19755969" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17916108" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23810085" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22344983" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699483" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138212" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11151879" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Infliximab in Crohn's disease: first anniversary clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11151882" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical experience with infliximab therapy in 100 patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29114832" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927075" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34051983" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24267474" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-αbiologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29610508" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : ACG Clinical Guideline: Management of Crohn's Disease in Adults.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
